金斯瑞生物(01548.HK)與命碼生物開展小核酸藥物臨床前合作
金斯瑞生物(01548.HK)宣布,與命碼生物就小核酸藥物臨床前研究展開合作,共共研發治療用小核酸項目,其中金斯瑞生物將為命碼生物提供小核酸臨床前研究服務,包含質粒合成、質粒生產工藝開發、製劑處方工藝研究等臨床申報整體方案,協助命碼生物獲得NMPA的臨床試驗批准。
公司表示,未來幾年將與命碼生物在臨床樣品GMP生產方面繼續合作,利用金斯瑞生物的cGMP質粒車間,完成藥物臨床樣品的生產。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.